Patents by Inventor Frederick M. Enright

Frederick M. Enright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120297493
    Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.
    Type: Application
    Filed: July 31, 2012
    Publication date: November 22, 2012
    Applicants: TransGenRx, Inc., The Board of Supervisors of Louisiana State Univ. and Agricultural and Mechanical College
    Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
  • Patent number: 8258100
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: September 4, 2012
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Patent number: 8236294
    Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: August 7, 2012
    Assignees: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, TransGenRx, Inc.
    Inventors: Richard K. Cooper, Frederick M. Enright, William C. Fioretti
  • Patent number: 8071364
    Abstract: Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: December 6, 2011
    Assignees: TransGenRx, Inc., The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
  • Publication number: 20110162096
    Abstract: Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human
    Type: Application
    Filed: November 8, 2010
    Publication date: June 30, 2011
    Applicants: College, TransGenRx, Inc.
    Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
  • Publication number: 20100199366
    Abstract: Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.
    Type: Application
    Filed: December 24, 2004
    Publication date: August 5, 2010
    Inventors: Richard Cooper, Frederick M. Enright, William C. Fioretti
  • Publication number: 20100016227
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Application
    Filed: June 19, 2009
    Publication date: January 21, 2010
    Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHNICAL COLLEGE
    Inventors: FREDERICK M. ENRIGHT, JESSE M. JAYNES, WILLIAM HANSEL, KENNETH L. KOONCE, SAMUEL M. MCCANN, WEN H. YU, PATRICIA A. MELROSE, LANE D. FOIL, PHILIP H. ELZER
  • Patent number: 7566777
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: July 28, 2009
    Assignee: Board of Supervisors of Louisana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Publication number: 20090047235
    Abstract: A paratransgenesis system is disclosed to kill targeted social insects such as termites and cockroaches, for example the Formosan subterranean termite. A genetically modified yeast can be effectively used to express and deliver lytic peptides directly within the termite gut. Some highly lytic peptides directly damage the insect gut itself, leading to the death of the insect within about three days. Other lytic peptides kill all (or at least most) species of protozoa in the termite gut. The protozoa provide wood-digesting enzymes (cellulases) to the termite. Without these protozoa (and their cellulases) the insect dies within about six weeks. The system is completely free from conventional neurotoxins and other organic pesticides.
    Type: Application
    Filed: May 15, 2008
    Publication date: February 19, 2009
    Inventors: Claudia R. Husseneder, James A. Ottea, Lane D. Foil, Frederick M. Enright, Richard K. Cooper
  • Patent number: 7262163
    Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% ?,?-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar ?,?-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: August 28, 2007
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
  • Publication number: 20040059088
    Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.
    Type: Application
    Filed: April 14, 2003
    Publication date: March 25, 2004
    Inventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
  • Publication number: 20040018967
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Application
    Filed: July 11, 2003
    Publication date: January 29, 2004
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Patent number: 6680058
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components—the ligand and the lytic peptide—may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: January 20, 2004
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Patricia A. Melrose, Philip H. Elzer
  • Patent number: 6635740
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: October 21, 2003
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Patent number: 6566334
    Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: May 20, 2003
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Mark L. McLaughlin, Thomas S. Yokum, Frederick M. Enright, Philip H. Elzer, Robert P. Hammer
  • Patent number: 6303568
    Abstract: A novel class of antimicrobial agents for animal species including cecropins, attacins, lysozymes, phage derived polypeptides, such as those transcribed from gene 13 of phage 22, an S protein from lambda phage, and an E protein from phage PhiXl74, as well as, synthetically derived polypeptides of similar nature. The antimicrobial agents can be used to treat microbial infections and as components of medicinal compositions. The genes encoding for such antimicrobial agents can be used to transform animal cells, especially embryonic cells. The transformed animals including such antimicrobial cells are also included.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: October 16, 2001
    Assignee: Helix Biomedix, Inc.
    Inventors: Jesse M. Jaynes, Frederick M. Enright, Kenneth L. White
  • Patent number: 6264952
    Abstract: Vaccines against facultative intracellular pathogens are disclosed. A host is vaccinated with non-viable but metabolically active agents. The non-viable agents produce immunogenic components that elicit protective host immune responses, with minimal likelihood of host infection by the vaccine agent. Living agents, either attenuated or virulent, are exposed to a dose of gamma irradiation (or other strong mutagen) that is sufficient to limit or prevent the replication of the agents within the host, but that is insufficient to stop the metabolic activities of the agent. In vitro exposure of a microbial agent to the damaging effects of gamma irradiation or of another strong mutagen induces certain stress responses in the infectious agent. These stress responses are similar to the stress responses that the virulent agent would produce within the tissues of the host.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: July 24, 2001
    Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Virginia Polytechnic Institute and State University, Board of Regents for Oklahoma State University, Cornell Research Foundation, Inc.
    Inventors: Frederick M. Enright, Alexander J. Winter, Gerhardt G. Schurig, John H. Wyckoff, III
  • Patent number: 6156568
    Abstract: Novel means have been discovered for increasing the resistance of an animal host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. The infection treated may, for example, be equine infectious anemia, or infection by the human immunodeficiency virus. Novel means have also been found for treating tumors. Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with an exogenous gene encoding a natural or synthetic lytic peptide. For example, the transfection of hematopoietic stem cells and embryonic cells will produce animals with enhanced disease resistance; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. Genes coding for a cecropin or other native or synthetic lytic peptide can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other animal cells.
    Type: Grant
    Filed: July 16, 1997
    Date of Patent: December 5, 2000
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Richard K. Cooper, Frederick M. Enright
  • Patent number: 5998698
    Abstract: Novel means have been discovered for increasing the resistance of an animal host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. The infection treated may, for example, be equine infectious anemia, or infection by the human immunodeficiency virus. Novel means have also been found for treating tumors Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with an exogenous gene encoding a natural or synthetic lytic peptide. For example, the transfection of hematopoietic stem cells and embryonic cells will produce animals with enhanced disease resistance; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. Genes coding for a cecropin or other native or synthetic lytic peptide can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other animal cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 7, 1999
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Richard K. Cooper, Frederick M. Enright
  • Patent number: 5556782
    Abstract: Novel means have been discovered for increasing the resistance of a mammalian host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. Novel means have also been found for treating tumors. Augmentation of the host's defenses against infectious diseases or tumors is achieved by "arming" the host's cells with a gene encoding the lytic peptide cecropin B. The host's own leukocytes, other cells involved in resistance to infection, or other cells are transformed, and expression of the gene is induced when needed to combat pathogens. Transfection of hematopoietic stem cells with the cecropin B gene will enhance disease resistance in mammals; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 17, 1996
    Assignee: Board of Supervisors of Louisiana State University and Agricultural & Mechanical College
    Inventors: Richard K. Cooper, Frederick M. Enright